Clinical trials: SCCHN
SCCHN
Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS
The nodal involvement in squamous cell carcinomas of the upper aerodigestive tract (VADS) is one of the main factors of poor prognosis, justifying the surgical management of neck dissection as a reference treatment.
- Trial name
- QDV2b (NCT02878655)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Head and Neck Neoplasms, AJCC Stage III/IV
Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck
To examine the safety and toxicity of concurrent radiotherapy with cisplatin with the further addition of cetuximab experimental treatment
- Trial name
- NCT01301248
- Testing
- Chemoradiation plus Cetuximab, Chemoradiation
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- Theagenio Cancer Hospital
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine the appropriate dose, that dose which is found to give maximum effect with limited toxicity, of cisplatin in combination with docetaxel and 5-fluorouracil and then to further define the…
- Conditions
- Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, SSCHN
- Trial name
- NCT00139269
- Testing
- Docetaxel, Cisplatin, 5-Fluorouracil
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Squamous Cell
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The aim of this prospective, observational, multicenter, post-marketing study is to evaluate the safety and efficacy of Cetuximab (Erbitux) in combination with platinum based chemotherapy, in the first line therapy of recurrent/…
- Trial name
- NCT01142869
- Testing
- Cetuximab
- Where
- 28 sites in India
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Squamous Cell Carcinoma of the Head and Neck
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following…
- Trial name
- NCT02769520
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Assuntina G. Sacco, MD
Head and Neck Cancer
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
This is a German, observational study in adult participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy, who start a new systemic therapy with nivolumab in…
- Trial name
- NCT03114163
- Where
- Germany
- Volunteers
- 485 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
This is a non-randomized, open-label phase II trial of 38 patients with recurrent or metastatic SCCHN. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 with good organ function and will be…
- Trial name
- NCT02124707
- Testing
- Cetuximab, Paclitaxel, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma of the Head and Neck
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
- Trial name
- NCT03880396
- Testing
- hypofractionated Rth with platinol
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Assiut University
Circulating Tumor Cell, Squamous Cell Carcinoma of the Head and Neck
CTC Detection Rate in SCCHN With a in Vivo Device
Detection rate and isolation yield of CTC is low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches rely on limited sample volumes.
- Trial name
- NCT03071900
- Testing
- circulating tumor cell analysis
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nanjing Tongren Hospital
Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and…
- Trial name
- NCT05751512
- Testing
- MRG003, Cetuximab injection, Methotrexate Injection
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Squamous Cell Cancer
Study of Sorafenib/Cetuximab in Head and Neck Cancer
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00815295
- Testing
- Sorafenib, Cetuximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Squamous Cell Carcinoma Head and Neck
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Phase II, Randomized, Non-Inferiority Study Comparing an Individualized Cancer Vaccine (AlloVax™) to Chemotherapy in Subjects with R/M SCCHN .
- Trial name
- NCT02624999
- Testing
- AlloVax™, Cisplatin
- Where
- Thailand
- Sponsor
- Mirror Biologics, Inc.
Squamous Cell Cancer of Head and Neck (SCCHN)
Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments…
- Trial name
- MIC-VADS (NCT07809100)
- Testing
- Tissue and secretion sampling via biopsy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Sud Francilien
Head and Neck Cancer
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
The goal of this clinical research study is to learn if adding erlotinib to a standard chemotherapy combination (docetaxel and either cisplatin or carboplatin) can help to control SCCHN.
- Trial name
- NCT01927744
- Testing
- Docetaxel, Erlotinib, Questionnaires
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
The aim of this trial is to examine the addition of docetaxel on disease progression, metastasis and survival of patients otherwise treated with SBRT and cetuximab alone.
- Trial name
- NCT02057107
- Testing
- SBRT, Cetuximab, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Heath Skinner